### Connecting via Winsock to STN

Welcome to STN International! Enter x:x LOGINID: SSSPTA1626KAS PASSWORD: TERMINAL (ENTER 1, 2, 3, OR ?):2 Welcome to STN International Web Page URLs for STN Seminar Schedule - N. America NEWS "Ask CAS" for self-help around the clock NEWS NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY OCT 03 MATHDI removed from STN NEWS 4 NEWS 5 OCT 04 CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices OCT 13 New CAS Information Use Policies Effective October 17, 2005 NEWS STN(R) AnaVist(TM), Version 1.01, allows the export/download NEWS 7 OCT 17 of CAplus documents for use in third-party analysis and visualization tools NEWS 8 OCT 27 Free KWIC format extended in full-text databases NEWS 9 OCT 27 DIOGENES content streamlined NEWS 10 OCT 27 EPFULL enhanced with additional content NEWS 11 NOV 14 CA/Caplus - Expanded coverage of German academic research NEWS EXPRESS NOVEMBER 18 CURRENT VERSION FOR WINDOWS IS V8.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005. V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT http://download.cas.org/express/v8.0-Discover/ NEWS HOURS STN Operating Hours Plus Help Desk Availability NEWS INTER General Internet Information NEWS LOGIN Welcome Banner and News Items Direct Dial and Telecommunication Network Access to STN NEWS PHONE NEWS WWW CAS World Wide Web Site (general information) Enter NEWS followed by the item number or name to see news on that specific topic. All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties. FILE 'HOME' ENTERED AT 14:06:24 ON 27 NOV 2005

SINCE FILE

ENTRY

TOTAL

SESSION

Page 1 saeed

COST IN U.S. DOLLARS

=> file reg

FULL ESTIMATED COST

0.21 0.21

FILE 'REGISTRY' ENTERED AT 14:06:39 ON 27 NOV 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 NOV 2005 HIGHEST RN 868737-05-7 DICTIONARY FILE UPDATES: 25 NOV 2005 HIGHEST RN 868737-05-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

Uploading C:\Program Files\Stnexp\Queries\10724683.str

```
chain nodes :
10 18 19
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16
ring/chain nodes :
20
chain bonds :
10-11 18-19 19-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16
exact/norm bonds :
5-7 6-9 7-8 8-9 18-19 19-20
exact bonds :
10-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
containing 11 :
```

#### Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS 20:CLASS 23:CLASS

#### L1 STRUCTURE UPLOADED

=> d L1 HAS NO ANSWERS L1 STR

Page 3 saeed

Structure attributes must be viewed using STN Express query preparation.

2 ANSWERS

=> s 11

SAMPLE SEARCH INITIATED 14:07:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4610 TO ITERATE

43.4% PROCESSED 2000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 88129 TO 96271 PROJECTED ANSWERS: 2 TO 220

L2 2 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 14:07:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 93691 TO ITERATE

100.0% PROCESSED 93691 ITERATIONS 48 ANSWERS

SEARCH TIME: 00.00.01

L3 48 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 161.33 161.54

Page 4 saeed

FILE 'CAPLUS' ENTERED AT 14:07:21 ON 27 NOV 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Nov 2005 VOL 143 ISS 23 FILE LAST UPDATED: 25 Nov 2005 (20051125/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 13 L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:490721 CAPLUS
DOCUMENT NUMBER: 141:54192
TITLE: Preparation of aminoalkoxyindoles as 5-HT6-receptor ligands, in particular selective 5-HT6 antagonists, for treating CNS disorders

LINVENTOR(S): Zhao, Shu-Hai
P. Hoffmann-La Roche A.-G., Switz.
SOURCE: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: PIKKD2
PAMILY ACC. NUM. COUNT: 1

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

	. PATENT NO.				KIN		DATE		APPLICATION NO.									
									WO 2003-EP13372									
	W:	AE.	AG.	AL,	AM.	AT,	AU,	AZ,	BA,	BB.	BG,	BR,	BY,	BZ.	CA,	CH,	CN,	
		co.	CR.	CU.	CZ.	DE.	DK.	DM,	DZ.	EC.	EE.	EG.	ES,	FI,	GB,	GD,	GE.	
		GH.	GM.	HR.	HU.	ID,	IL.	IN,	IS,	JP.	KE.	KG.	KP,	KR.	KZ,	LC,	LK.	
		LR.	LS.	LT.	LU.	LV.	HA.	MD,	MG.	MK.	MN,	MW.	MX,	MZ.	NI.	NO.	NZ.	
		OM.	PG.	PH.	PL.	PT.	RO.	RU,	sc.	SD.	SE.	SG,	SK.	SL.	SY.	TJ.	TM.	
		TN.	TR.	TT.	TZ.	UA,	UG,	UZ.	VC.	VN.	YU,	ZA.	ZM,	ZW				
	RW:	BW.	GH.	GM.	KE.	LS,	MW.	MZ.	SD.	SL.	sz,	TZ.	UG,	ZM.	ZW.	AM,	AZ.	
											BG,							
											MC,							
											GQ,							T
CA	2508																	
EP	EP 1569638				A1 20050907			EP 2003-782240						20031127				
											IT,							
											TR,						,	
US	2004	1327	99 .		Al		2004	0708		US 2	2003-	7246	83 ^		2	0031	201	
PRIORIT	US 2004132799 RIORITY APPLN. INFO.:								US 2	002-	4305	06P	1	P 2	0021	203		
											2003-							
OTHER S	OURCE	(5):			MAR	PAT	141:	5419							_			

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

TRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA CEPTINE FARM.

Title compds. I [wherein m = 0-3; n = 0-2; each Rl = independently H, halo, halo/hetero/alkyl, OR and derivs., NO2, CN, NH2 and derivs., COMH2 and derivs., SO2NH2 and derivs., SC2NH2 and derivs., SC2NH2 and derivs., SC2NH2 and derivs., SC2NH2, and the standard to the scale of the scale

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
N-[2-[(3-Benzenswifonyl-iH-indol-7-yl) oxylethyl]dimethylamine
monohydrochloride 706783-75-7e, N-[2-[(3-[2Mathoxybenzeneswifonyl]-iH-indol-7-yl) oxylethyl]dimethylamine
monohydrochloride 706783-76-8e, N-[2-[(3-[2Fluorobenzeneswifonyl]-iH-indol-7-yl) oxylethyl]dimethylamine
monohydrochloride 706783-77-9e, N-[2-[(3-[2Fluorobenzeneswifonyl]-iH-indol-7-yl) oxylethyl] methylamine
monohydrochloride 706783-78-9e, N-[2-[(3-Benzeneswifonyl-iHindol-7-yl) oxylethyl] methylamine monohydrochloride 706783-79-11e,
indol-7-yl) oxylethyl]methylamine monohydrochloride 706783-79-11e,
indol-7-yl) oxylethyl]methylamine monohydrochloride 706783-83-7e,
N-[2-[(2-Benzeneswifonyl-i-H-indol-7-yl) oxylethyl]methylamine
monohydrochloride 706783-8e-9, N-[2-[(2-Benzeneswifonyl-iHindol-4-yl) oxylethyl]methylamine monohydrochloride 706783-83-7e,
N-[2-[(2-Benzeneswifonyl-iH-indol-7-yl) oxylethyl]methylamine
monohydrochloride 706783-89-9, 3-[2,5-bichlorobenzeneswifonyl-]7-[2-[vyrrolidin-1-yl) ethoxyl-iH-indole monohydrochloride
706784-05-99, 2-Benzeneswifonyl-3-1P, [2-[(3-[2-Fluorobenzeneswifonyl-]+H-indol-77010xylethyl]dimethylamine 706784-3-19, 3-[2,5Bichlorobenzeneswifonyl-7-[2-[vyrrolidin-1-yl]ethoxyl-iH-indol-7706784-32-99, 2-Benzeneswifonyl-7-[2-[vyrrolidin-1-yl]ethoxyl-iH-indole
706784-33-29, 3-Benzeneswifonyl-7-[2-[vyrrolidin-1-yl]ethoxyl-iH-indole
706784-33-29, 3-Benzeneswifonyl-7-[2-[vyrrolidin-1-yl]ethoxyl-iH-indole
706784-39-59, 3-[2,3-Bichlorobenzeneswifonyl-7-[2-[vyrrolidin-1-yl]ethoxyl-iH-indole
706784-39-59, 3-[2,3-Bichlorobenzeneswifonyl-7-[2-[vyrrolidin-1-yl]ethoxyl-IH-indole
706784-39-59, 3-[2,3-Bichlorobenzeneswifonyl-7-[2-[vyrrolidin-1-yl]ethoxyl-IH-indole
706784-39-59, 3-[2-Bichlorobenzeneswifonyl-7-[2-[vyrrolidin-1-yl]ethoxyl-IH-indole
706784-39-59, 3-[2-[vyrolidin-1-yl]ethoxyl-1H-indole
706784-39-59, 3-[2-[vyrolidin-1-yl]ethoxyl-IH-indole
706784-39-59, 3-[2-[vyrolidin-1-yl]ethoxyl-IH-indole
706784-39-59, 3-[2-[vyrolidin-1-yl]ethoxyl-IH-indole
706

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
be selective 5-HT6 antagonists.
706784-16-99, N-[2-[[3-[8benzensulfony1]-1H-indol-7ylloxy]ethyl]methylamine 706784-30-79, [2-[[3-{2Plucrobenzensulfony1]-1H-indol-7-yl]oxy]ethyl]amine
RL: PAC (Pharmacological activity), RCT (Reactant) SFN (Synthetic
preparation), TRU (Therapsulic use), BIOL (Biological study), PREP
(Preparation), RACT (Reactant or reagent), USES (Uses)
(5-HT6 antagonist, preparation of aminoslkoxyindoles as 5-HT6-receptor
ligands, in particular selective 5-HT6 antagonists, for treating CNS
disorders)
706784-16-9 CAPLUS
Ethanamine, N-methyl-2-[[3-(phenylsulfonyl)-1H-indol-7-yl]oxy]- (9CI) (CA
INDEX NAME)

MeNH-CH2-CH2

706784-30-7 CAPLUS Ethanamine, 2-[[3-[(2-fluorophenyl)sulfonyl]-1H-indol-7-yl]oxy]- (9CI) (CA INDEX NAME)

H2N-CH2-CH2

706783-64-4P, 3-Benzenesulfonyl-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-65-59, 3-(3-Chlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706793-66-69, 3-(4-Chlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706793-67-79, 3-(4-Chlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-68-89, 3-(2-Chlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-68-99, 3-(3-Florobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-71-39, 3-(2-Florobenzenesulfonyl)-7-(2-(pyrrolidin-1-yl)ethoxyl-1H-indole monohydrochloride 706783-71-39, 3-(3-Florobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxyl-1H-indole monohydrochloride 706783-71-39, 3-(3-Florobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxyl-1H-indole monohydrochloride 706783-73-59, 3-(2-Hethoxybenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxyl-1H-indole monohydrochloride 706783-73-59, 3-(2-Hethoxybenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxyl-1H-indole monohydrochloride 706783-73-59, 3-(2-Hethoxybenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxyl-1H-indole monohydrochloride 706783-74-69,

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

● HCl

706783-65-5 CAPLUS
IH-Indole, 3-((3-chlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-,
monohydrochloride (9CI) (CA INDEX NAME)

● HC1

706783-66-6 CAPLUS IH-Indole, 3-((4-chlorophenyl)sulfonyl}-7-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued

● HCI

RN 706783-67-7 CAPLUS
CN IH-Indole, 3-[(2,3-dichlorophenyl) sulfonyl]-7-[2-(1-pyrrolidinyl) ethoxy)-,
monohydrochloride (9CI) (CA INDEX NAME)

● HC1

RN 706783-68-8 CAPLUS
CN 1H-Indole, 3-[(2-chlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy)-,
monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued

• HCl

RN 706783-71-3 CAPLUS
CN .1H-Indole, 3-[(3-fluorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

• HC1

RN 706783-72-4 CAPLUS
CN IH-indole, 3-[(3-methoxyphenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-,
monohydrochloride (SCI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued

● HCl

RN 706783-69-9 CAPLUS
CN HH-Indole, 3-[(3,4-dichlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-,
monohydrochloride (9CI) (CA INDEX NAME)

• HC1

RN 706783-70-2 CAPLUS
CN 1H-Indole, 3-[(2-fluorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-,
monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

• HCl

RN 706783-73-5 CAPLUS
CN H-Indole, 3-[(2-methoxyphenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-,
monohydrochloride (9CI) (CA INDEX NAME)

● HC1

RN 706783-74-6 CAPLUS The state of the st

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Me<sub>2</sub>N-CH<sub>2</sub>-CH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>1</sub>

• HCl

RN 706783-75-7 CAPLUS
CN Ethansmine, 2-[[3-[(2-methoxyphenyl)sulfonyl]-1H-indol-7-yl]oxy]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

MegN-CH2-CH2-CH2-OHe

• HC1

RN 706783-76-8 CAPLUS
CN Ethanamine, 2-[[3-[(2-fluorophenyl)sulfonyl]-lH-indol-7-yl]oxy]-N,Ndimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Me2N-CH2-CH2-CH2-

• HCl

RN 706783-77-9 CAPLUS
CN Ethanamine, 2-[[3-[(2-fluorophenyl)sulfonyl]-1H-indol-7-yl]oxy]-N-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Ethanamine, N-methyl-2-[(2-(phenylsulfonyl)-lH-indol-4-yl]oxy]-,
monohydrochloride (9CI) (CA INDEX NAME)

MeNH-CH2-CH2-OH-Ph

• HCl

RN 706783-83-7 CAPLUS
CN Ethanamine, N-methyl-2-[{2-(phenylsulfonyl)-lH-indol-7-yl]oxy]-,
monohydrochloride {9Cl} (CA INDEX NAME)

MeNIH-CH2-CH2-0 H S-Ph

• HC

RN 706783-84-8 CAPLUS
CN IH-Indole, 3-[(2,5-dichloropheny1) sulfony1]-7-[2-(1-pyrrolidiny1) ethoxy]-,
monohydrochloride (SCI) (CA INDEX NAME)

• HC1

Page 8

saeed

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Menh-Ch2-Ch2-Ch4-

● HC

RN 706783-78-0 CAFLUS
CN Ethanamine, N-methyl-2-[[3-(phenylsulfonyl)-lH-indol-7-yl]oxy]-,
monohydrochloride (9CI) (CA INDEX NAME)

Menia Ch2 Ch2 Ph

• HCl

RN 706783-79-1 CAPLUS
CN Ethanamine, N-methyl-2-[[1-methyl-3-(phenylsulfonyl)-lH-indol-7-yl]oxy]-,
monohydrochloride (9CI) (CA INDEX NAME)

CES-Ph

● HC

RN 706783-82-6 CAPLUS

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 706783-85-9 CAPLUS
CN 1H-Indole, 2-(phenylsulfonyl)-4-[2-(1-pyrrolidinyl)ethoxy]-,
monohydrochloride (9CI) (CA INDEX NAME)

CH2 CH2 CH2

O HC1

RN 706783-87-1 CAPLUS
CN Ethanamine, 2-[[3-[(2-fluorophenyl)sulfonyl]-1H-indol-7-yl]oxy]-,
monohydrochloride (9CI) (CA INDEX NAME)

H<sub>2</sub>N-CH<sub>2</sub>-CH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-OH<sub>2</sub>-

• HCl

RN 706784-06-7 CAPLUS
CN Ethanamine, 2-[[3-[(2-fluorophenyl)sulfonyl]-1H-indol-7-yl)oxy]-N,N-dimethyl- (9C1) (CA INDEX NAME)

Me<sub>2</sub>N-CH<sub>2</sub>-CH<sub>2</sub>-0

RN 706784-07-8 CAPLUS

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Indole, 3-[(2,5-dichlorophenyl)sulfonyl)-7-[2-(1-pyrrolidinyl)ethoxy](9C1) (CA 1MDEX NAME)

RN 706784-23-8 CAPLUS
CN 1H-Indole, 2-(phenylsulfonyl)-4-(2-(1-pyrrolidinyl)ethoxy)- (9CI) (CA INDEX NAME)

RN 706784-35-2 CAPLUS CN IH-Indole, 3-(phenylsulfonyl)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME) L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 706784-36-3 CAPLUS
CN HH-Indole, 3-[(3-chlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy](SCI) (CA INDEX NAME)

RN 706784-37-4 CAPLUS
CN HH-Indole, 3-[(4-chlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy](SCI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued

RN 706784-38-5 CAPLUS
CN 1H-Indole, 3-[(2,3-dichlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy](9CI) (CA INDEX NAME)

RN 706784-39-6 CAPLUS
CN HH-Indole, 3-({2-chlorophenyl})sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy](SCI) (CA INDEX (NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 706784-40-9 CAPLUS
CN HH-Indole, 3-[(3,4-dichlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy](9C1) (CA INDEX NAME)

RN 706784-41-0 CAPLUS
CN 1H-Indole, 3-[(2-fluorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy](9CI) (CA INDEX NAME)

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

706784-42-1 CAPLUS HH-Indole, 3-((3-fluorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-(SCI) (CA INDEX NAME)

706784-43-2 CAPLUS IH-Indole, 3-[(3-methoxyphenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-(SCI) (CA INDEX NAME)

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) 706784-46-5 CAPLUS Ethanamine, 2-[[3-[(2-methoxyphenyl)sulfonyl]-1H-indol-7-yl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Me 2N-CH2-CH2-

706784-47-6 CAPLUS Ethanamine, 2-[[3-([2-fluorophenyl]sulfonyl]-lH-indol-7-yl]oxyl-N-methyl-(SCI) (CA INDEX NAME)

Menh-CH2-CH2-

706784-48-7 CAPLUS Ethanamine, N-methyl-2-{[1-methyl-3-{phenylsulfonyl}-1H-indol-7-yl}oxy]-(9CI) (CA INDEX NAME)

706784-51-2 CAPLUS Ethananine, N-methyl-2-[[2-(phenylsulfonyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

Menh CH2 CH2

706784-52-3 CAPLUS

Page 10 saeed L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

706784-44-3 CAPLUS Hi-Indole, 3-[42-methoxyphenyl] sulfonyl]-7-[2-(1-pyrrolidinyl]ethoxy]-(9C1) (CA INDEX NAME)

706784-45-4 CAPLUS Ethanamine, N.N-dimethyl-2-[[3-(phenylsulfonyl)-1H-indol-7-yl]oxy]- (9CI) (CA INDEX NAME)

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) Ethanamine, N-methyl-2-[[2-(phenylsulfonyl)-1H-indol-7-yl]oxy]- (9CI) (CA INDEX NAME)

706784-13-6P, [2-[(3-(2-(Fluoro)banzenesulfonyl)-1H-indol-7-yl] oxy]ethyl] (methyl) carbamic acid tert-butyl ester 706784-17-0P, [2-[(3-(2-Fluorobenzenesulfonyl)-1-methyl-1H-indol-7-yl] oxy]ethyl] (methyl) carbamic acid tert-butyl ester 706784-20-5P, 2-Benzenesulfonyl-4-[2-((tert-butoxycarbonyl) (methyl) amino]ethoxy]indole-1-carboxylic acid tert-butyl ester 706784-22-7P, 2-Benzenesulfonyl-7-[2-[(tert-butoxycarbonyl) (methyl) amino]ethoxy]indole-1-carboxylic acid tert-butyl ester 706784-27-2P, 2-Benzenesulfonyl-4-[2-(pyrrolidin-1-yl)ethoxy]indole-1-carboxylic acid tert-butyl ester 2-Benzenesuriony: -- [2-[pyriotizin - , , , , ]

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of aminoalkoxyindoles as 5-HT6-receptor

ligands, in particular selective 5-HT6 antagonists, for treating CNS disorders)
706784-13-6 CAPIUS
Carbamic acid, [2-[[3-[(2-fluorophenyl)sulfonyl]-1H-indol-7yl]oxy]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

0 Me || | t-Bu0-C-N-CH2-CH2-

706784-17-0 CAPLUS
Carbamic acid, [2-[[3-[(2-fluorophenyl)sulfonyl]-1-methyl-1H-indol-7-yl]oxy]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 10.33 171.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL ENTRY SESSION

CA SUBSCRIBER PRICE -1.46 -1.46

STN INTERNATIONAL LOGOFF AT 14:07:58 ON 27 NOV 2005